Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel

By Jessica Bylander / Email the Author / “The Gray Sheet” Jul. 20, 2009, Vol. 35, No. 029
Advisory Panels / Word Count: 265 / Article # 01350290016

Executive Summary

FDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 265-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
Companies
Johnson & Johnson
DePuy Inc.
DePuy Orthopaedics Inc.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Gray Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel